Net product sales grew 26% year-over-year to $54.9 million.
Repaid $45M term loan and transitioned to a flexible revolving credit facility.
Achieved gross margins exceeding 92% on product sales.
Termination of the strategic collaboration agreement with Eli Lilly.
Rigel Pharmaceuticals stands at a critical inflection point where commercial success is battling structural financial risks. The surge in product sales and the move toward a debt-free operating model are strong bullish signals, suggesting the company can sustain itself through its own revenue engine. However, the underlying cash burn and the loss of the Lilly partnership introduce significant volatility. Investors must weigh the high-margin product growth against the concentration risk and the potential for a cash crunch if the R289 pipeline does not yield a commercial catalyst soon. The overall impact of the filing is a company with a proven product portfolio but a precarious balance sheet that leaves little room for further regulatory or commercial setbacks.